AMZN
Amazon.com, Inc.
AMZN has the edge over MUSA overall, supported by stronger valuation and stronger modeled upside.
MUSA
Murphy USA Inc.
MUSA offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
MUSA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
MUSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over MUSA in the historical PE scenario, which offers more potential upside but is not a forecast.
MUSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $385 | -28% |
| Fair | 15x | $534 | -0.1% |
| Current | 15x | $535 | — |
| Forward | 18x | $535 | — |
| Expensive | 20x | $697 | +30% |
Historical ranges are pointers, not guarantees.
MUSA's PE is in its fair range at 15x. On analysts' estimates for next year's earnings, today's price would be 18x, in its expensive range.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over MUSA on the outlook, with more favorable earnings and profitability expectations.
MUSA Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Stable | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect MUSA's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over MUSA on earnings, with more consistent year-over-year improvement.
MUSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.88 | -16% |
| Q3 2026 | $35.49 | +50% |
| Q2 2026 | $32.66 | +36% |
| Q1 2026 | $28.75 | +22% |
| Q4 2025 | $24.10 | 0% |
| Q3 2025 | $23.62 | -2.5% |
| Q2 2025 | $24.06 | -2.6% |
| Q1 2025 | $23.62 | -0.8% |
| Q4 2024 | $24.11 | -5.4% |
MUSA earned $35.49 per share over the past year, up 50% from the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over MUSA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over MUSA on profitability, with a higher operating margin.
MUSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6.9B | +35% |
| Q2 2026 | $6.8B | +36% |
| Q1 2026 | $4.8B | +6.5% |
| Q4 2025 | $4.7B | +0.7% |
| Q3 2025 | $5.1B | -2.5% |
| Q2 2025 | $5B | -8.2% |
| Q1 2025 | $4.5B | -6.6% |
| Q4 2024 | $4.7B | -7.1% |
MUSA's revenue has grown year over year for four quarters in a row: $6.9B last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.8% | -0.2 points |
| Q2 2026 | 4.5% | +0.1 points |
| Q1 2026 | 4.3% | +2.3 points |
| Q4 2025 | 4.4% | +0.2 points |
| Q3 2025 | 4% | -0.3 points |
| Q2 2025 | 4.4% | +0.4 points |
| Q1 2025 | 1.9% | -0.2 points |
| Q4 2024 | 4.2% | -0.1 points |
MUSA's operating margin was 3.8% last quarter, about level with the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
MUSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $193.7M | +186% |
| Q2 2026 | $123.3M | -10% |
| Q1 2026 | $221.7M | +445% |
| Q4 2025 | $128.8M | +5.8% |
| Q3 2025 | $67.7M | +3.8% |
| Q2 2025 | $137.1M | -4% |
| Q1 2025 | $40.7M | -32% |
| Q4 2024 | $121.7M | -25% |
MUSA has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
MUSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -192K shares |
| 1 year | -4.5% | -872K shares |
| 3 years | -16% | -3.4M shares |
| 5 years | -30% | -7.8M shares |
| Available history | -42% | -13.5M shares |
MUSA has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $156.2M |
| Q2 2026 | $82.3M |
| Q1 2026 | $70.5M |
| Q4 2025 | $66.9M |
| Q3 2025 | $219.2M |
| Q2 2025 | $213.8M |
| Q1 2025 | $150M |
| Q4 2024 | $128M |
MUSA spent $376M buying back its own shares over the past year, down 47% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over MUSA on leverage, with a lower net debt burden relative to earnings.
MUSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 2.2x | Moderate |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 1.8x | Healthy |
MUSA's net debt is about 1.6 years of its operating earnings (EBITDA), down from 2.2 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
MUSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 37.4 | Neutral |
MUSA's weekly RSI is 51 (neutral) and its Stochastic is 37 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
MUSA PE vs Consumer Cyclical Sector
| Metric | MUSA | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 18x | 16% below |
| PE % | 50 | 47 | 3 pts above |
MUSA has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over MUSA on trend strength, trading above more of its moving averages.
MUSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $528.7 | 1.1% above |
| 20 week MA | $547.2 | 2.3% below |
| 50 week MA | $503.4 | 6.2% above |
| 100 week MA | $467.6 | 14% above |
| 200 week MA | $425.8 | 26% above |
MUSA's trend is mixed: it's above four of its five weekly moving averages, and 26% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
MUSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $119.5 | $130.2 | +8.9% |
| 2021 | $130.2 | $191.6 | +47% |
| 2022 | $191.6 | $293.4 | +53% |
| 2023 | $293.4 | $356.6 | +22% |
| 2024 | $356.6 | $505.2 | +42% |
| 2025 | $505.2 | $405.0 | -20% |
| 2026 YTD | $405.0 | $534.7 | +32% |
MUSA has the edge over AMZN on returns for 2026, with the stronger performance.